

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6413727

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
IMKE ELISABETH MULDER	02/12/2020
ANNA ETTORRE	03/25/2020
SUAAD AHMED	02/12/2020
PARTHENA FOTIADOU	02/12/2020
SAMANTHA YUILLE	02/12/2020
JOSEPH ROBY IRINGAN URCIA	03/28/2020
HELENE SAVIGNAC	05/02/2020
RECEIVING PARTY DATA	
Name:	4D PHARMA RESEARCH LIMITED
Street Address:	LIFE SCIENCES INNOVATION BUILDING
Internal Address:	CORNHILL ROAD
City:	ABERDEEN
State/Country:	UNITED KINGDOM
Postal Code:	AB25 2ZS
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16713911
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6504939300
Email:	rrsmith@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	56708-727.301
NAME OF SUBMITTER:	MOONKYOUNG UM
SIGNATURE:	/Moonkyoung Um/

DATE SIGNED:	11/21/2020
Total Attachments: 8 source=56708-727.301 - Executed Assignment (all inventors)#page1.tif source=56708-727.301 - Executed Assignment (all inventors)#page2.tif source=56708-727.301 - Executed Assignment (all inventors)#page3.tif source=56708-727.301 - Executed Assignment (all inventors)#page4.tif source=56708-727.301 - Executed Assignment (all inventors)#page5.tif source=56708-727.301 - Executed Assignment (all inventors)#page6.tif source=56708-727.301 - Executed Assignment (all inventors)#page7.tif source=56708-727.301 - Executed Assignment (all inventors)#page8.tif	

PATENT ASSIGNMENT

Docket Number 56708-727.301

WHEREAS, the undersigned:

1. Imke Elisabeth MULDER
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

3. Suaad AHMED
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

5. Samantha YUILLE
27 Auchmill Terrace, Bucksburn
Aberdeen, GB AB21 9LF

7. Helene SAVIGNAC
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

2. Anna ETTORE
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

4. Parthena FOTIADOU
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

6. Joseph Roby Irgan URCIA
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

COMPOSITIONS COMPRISING BACTERIAL STRAINS

- ☐ for which a United States patent application is executed on even date herewith;
☒ for which application serial number 16/713,911 was filed on December 13, 2019 in the United States Patent and Trademark Office;
☐ for which a PCT application serial number _____ was filed on _____ in the [] Receiving Office of the Patent Cooperation Treaty;
☐ for which application serial number _____ was filed on _____ in the _____ Patent Office;
☐ for which an application was filed upon which a United States Patent issued on _____ as U.S. Patent No. _____; or
☐ for which a PCT application will be filed on or before [insert 12-month date] in the [] Receiving Office of the Patent Cooperation Treaty

which will claim priority to [_____].

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, 4D Pharma Research Limited, a corporation incorporated under the laws of the country of Great Britain, having a place of business at Life Sciences Innovation Building, Cornhill Road, Aberdeen, GB AB25 2ZS, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)")

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal

PATENT ASSIGNMENT

Docket Number 56708-727.301

representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the country of Great Britain, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: <u>12 Feb 2020</u>	<u>[Signature]</u> Imke Elisabeth MULDER	Date: _____	_____
Date: <u>12 Feb 2020</u>	<u>[Signature]</u> Suaad AHMED	Date: <u>12 02 20</u>	<u>[Signature]</u> Parthena FOTIADOU
Date: <u>12 Feb 2020</u>	<u>[Signature]</u> Samantha YUILLE	Date: _____	_____
Date: _____	_____	_____	_____
Date: _____	_____	_____	_____

RECEIVED AND AGREED TO BY ASSIGNEE: 4D Pharma Research Limited

Date: 11 February 2020 Signature: [Signature]
Name: ALEXANDER SWANSON
Title: Director, Chief Scientific Officer

WHEREAS, the undersigned:

- | | |
|---|--|
| <p>1. Imke Elisabeth MULDER
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS</p> | <p>2. Anna ETTORE
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS</p> |
| <p>3. Suaad AHMED
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS</p> | <p>4. Parthena FOTIADOU
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS</p> |
| <p>5. Samantha YUILLE
27 Auchmill Terrace, Bucksburn
Aberdeen, GB AB21 9LF</p> | <p>6. Joseph Roby Iringan URCLIA
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS</p> |
| <p>7. Helene SAVIGNAC
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS</p> | |

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

COMPOSITIONS COMPRISING BACTERIAL STRAINS

- ☐ for which a United States patent application is executed on even date herewith;
- ☒ for which application serial number 16/713,911 was filed on December 13, 2019 in the United States Patent and Trademark Office;
- ☐ for which a PCT application serial number _____ was filed on _____ in the [] Receiving Office of the Patent Cooperation Treaty;
- ☐ for which application serial number _____ was filed on _____ in the _____ Patent Office;
- ☐ for which an application was filed upon which a United States Patent issued on _____, as U.S. Patent No. _____; or
- ☐ for which a PCT application will be filed on or before [insert 12-month date] in the [] Receiving Office of the Patent Cooperation Treaty

which will claim priority to [_____].

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, 4D Pharma Research Limited, a corporation incorporated under the laws of the country of Great Britain, having a place of business at Life Sciences Innovation Building, Cornhill Road, Aberdeen, GB AB25 2ZS, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal

PATENT ASSIGNMENT

Docket Number 56708-727.301

representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the country of Great Britain, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____

Inke Elisabeth MULDER

Date: 25/03/2020Anne ETTORRE
Anne ETTORRE

Date: _____

Suad AHMED

Date: _____

Parthena FOTIADOU

Date: _____

Samantha VUILLE

Date: _____

Joseph Roby Ingram URCLA

Date: _____

Helene SAVIGNAC

RECEIVED AND AGREED TO BY ASSIGNEE: 4D Pharma Research Limited

Date: 1 April 2020Signature: 

Name: Alexander Stevenson

Title: Director, Chief Scientific Officer

PATENT ASSIGNMENT

Docket Number 56708-727.301

WHEREAS, the undersigned:

1. Imke Elisabeth MULDER
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

2. Anna ETTORRE
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

3. Suaad AHMED
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

4. Parthena FOTIADOU
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

5. Samantha YUILLIE
27 Auchmill Terrace, Bucksburn
Aberdeen, GB AB21 9LF

6. Joseph Roby Iringan URCLIA
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

7. Helene SAVIGNAC
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

COMPOSITIONS COMPRISING BACTERIAL STRAINS

- ☐ for which a United States patent application is executed on even date herewith;
☒ for which application serial number 16/713,911 was filed on December 13, 2019 in the United States Patent and Trademark Office;
☐ for which a PCT application serial number _____ was filed on _____ in the [] Receiving Office of the Patent Cooperation Treaty;
☐ for which application serial number _____ was filed on _____ in the _____ Patent Office;
☐ for which an application was filed upon which a United States Patent issued on _____, as U.S. Patent No. _____; or
☐ for which a PCT application will be filed on or before [insert 12-month date] in the [] Receiving Office of the Patent Cooperation Treaty

which will claim priority to [_____].

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, 4D Pharma Research Limited, a corporation incorporated under the laws of the country of Great Britain, having a place of business at Life Sciences Innovation Building, Cornhill Road, Aberdeen, GB AB25 2ZS, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:



1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal

PATENT ASSIGNMENT		Docket Number 56708-727.301	
representatives and assigns.			
6. This instrument will be interpreted and construed in accordance with the laws of the country of Great Britain, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.			
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:			
Date: _____	Imke Elisabeth MULDER	Date: _____	Anna ETTORRE
Date: _____	Suaad AHMED	Date: _____	Parthena FOTIADOU
Date: _____	Samantha YUILLE	Date: _____	Joseph Roby Iringan URCIA
Date: 02.05.20	Helene SAVIGNAC 		
RECEIVED AND AGREED TO BY ASSIGNEE: 4D Pharma Research Limited			
Date: 7 MAY '20	Signature: 	Name:	Title:

PATENT ASSIGNMENT

Docket Number 56708-727.301

WHEREAS, the undersigned:

1. Inke Elisabeth MULDER
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS
3. Suaad AHMED
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS
5. Samantha YUILLE
27 Auchmill Terrace, Bucksburn
Aberdeen, GB AB21 9LF
7. Helene SAVIGNAC
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

2. Anna ETTORRE
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS
4. Parthena FOTIADOU
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS
6. Joseph Roby Iringan URCIA
c/o 4D Pharma Research Limited
Life Sciences Innovation Building, Cornhill Road
Aberdeen, GB AB25 2ZS

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

COMPOSITIONS COMPRISING BACTERIAL STRAINS

- ☐ for which a United States patent application is executed on even date herewith;
- ☒ for which application serial number 16713911 was filed on December 13, 2019 in the United States Patent and Trademark Office;
- ☐ for which a PCT application serial number _____ was filed on _____ in the [] Receiving Office of the Patent Cooperation Treaty;
- ☐ for which application serial number _____ was filed on _____ in the _____ Patent Office;
- ☐ for which an application was filed upon which a United States Patent issued on _____, as U.S. Patent No. _____; or
- ☐ for which a PCT application will be filed on or before [insert 12-month date] in the [] Receiving Office of the Patent Cooperation Treaty

which will claim priority to [_____].

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, 4D Pharma Research Limited, a corporation incorporated under the laws of the country of Great Britain, having a place of business at Life Sciences Innovation Building, Cornhill Road, Aberdeen, GB AB25 2ZS, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:


1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal

PATENT ASSIGNMENT		Docket Number 56708-727.301
<p>representatives and assigns.</p> <p>6. This instrument will be interpreted and construed in accordance with the laws of the country of Great Britain, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.</p> <p style="text-align: center;">IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:</p>		
Date: _____	<p>_____</p> <p>Imke Elisabeth MULDER</p>	<p>Date: _____</p> <p>_____</p> <p>Anna ETTORRE</p>
Date: _____	<p>_____</p> <p>Saad AHMED</p>	<p>Date: _____</p> <p>_____</p> <p>Parthena FOTIADOU</p>
Date: _____	<p>_____</p> <p>Samantha YUILLE</p>	<p>Date: <u>23 March 2020</u></p> <p>_____</p> <p>Joseph Roby Iringan URCIA</p>
Date: _____	<p>_____</p> <p>Helene SAVIGNAC</p>	
<p>RECEIVED AND AGREED TO BY ASSIGNEE: 4D Pharma Research Limited</p> <p>Date: <u>22 April 2020</u> Signature: </p> <p style="margin-left: 150px;">Name: Alexander Stevenson</p> <p style="margin-left: 150px;">Title: Director, Chief Scientific Officer</p>		